Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy

Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy

Spyridon Dimopoulos, Martin Alexander Leitritz, Focke Ziemssen, Bogomil Voykov, Karl Ulrich Bartz-Schmidt, Faik Gelisken Centre for Ophthalmology, Eberhard-Karls University, Tuebingen, Germany Purpose: To report the visual and morphological outcomes following intravitreal bevacizumab in n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dimopoulos S, Leitritz MA, Ziemssen F, Voykov B, Bartz-Schmidt KU, Gelisken F
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/9034900ce5ab4af9b780bdcda8e03e5c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9034900ce5ab4af9b780bdcda8e03e5c
record_format dspace
spelling oai:doaj.org-article:9034900ce5ab4af9b780bdcda8e03e5c2021-12-02T07:20:19ZSubmacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy1177-5483https://doaj.org/article/9034900ce5ab4af9b780bdcda8e03e5c2015-08-01T00:00:00Zhttp://www.dovepress.com/submacular-predominantly-hemorrhagic-choroidal-neovascularization-reso-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Spyridon Dimopoulos, Martin Alexander Leitritz, Focke Ziemssen, Bogomil Voykov, Karl Ulrich Bartz-Schmidt, Faik Gelisken Centre for Ophthalmology, Eberhard-Karls University, Tuebingen, Germany Purpose: To report the visual and morphological outcomes following intravitreal bevacizumab in neovascular age-related macular degeneration (nAMD) with submacular, predominantly hemorrhagic, lesions.Methods: Retrospective study of patients with a follow-up after 1 year. All eyes with submacular hemorrhages larger than 50% of the total lesion size and received only anti-VEGF (vascular endothelial growth factor) monotherapy (intravitreous administration of 1.25 mg bevacizumab, PRN). The primary endpoint was the change in hemorrhage size and time to resolution, in association with the mean best-corrected visual acuity (BCVA). The eyes were grouped based on the size of the hemorrhage: group A (≥1 to <4 disc area [DA]), group B (≥4 to <9 DA), and group C (≥9 DA).Results: Forty-six consecutive eyes were included. The mean area of the hemorrhage was 6 DA at baseline. Eyes with smaller bleeding (group A) had better chances of stabilized or improved vision. Complete resolution of the hemorrhage was seen in 96% of the eyes within 1 year. The mean BCVA increased from 0.81 logarithm of the minimum angle of resolution (logMAR) (95% confidence interval [CI]: 0.70–0.92) (Snellen 20/125) at baseline to 0.75 logMAR (95% CI: 0.62–0.88) (20/125) after 1 year (P=0.11). BCVA improved (one or more ETDRS [Early Treatment of Diabetic Retinopathy Study] lines) in 57% of the eyes (13/23) in group A; 53% (8/15) in group B; and 38% (3/8) in group C.Conclusion: Many of the eyes with hemorrhagic lesions showed stabilization or improvement of the mean BCVA after treatment within 1 year. Anti-VEGF treatment can be considered as a useful treatment option in eyes with hemorrhages secondary to nAMD. Keywords: age-related macular degeneration, bevacizumab, submacular hemorrhageDimopoulos SLeitritz MAZiemssen FVoykov BBartz-Schmidt KUGelisken FDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 1537-1541 (2015)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Dimopoulos S
Leitritz MA
Ziemssen F
Voykov B
Bartz-Schmidt KU
Gelisken F
Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
description Spyridon Dimopoulos, Martin Alexander Leitritz, Focke Ziemssen, Bogomil Voykov, Karl Ulrich Bartz-Schmidt, Faik Gelisken Centre for Ophthalmology, Eberhard-Karls University, Tuebingen, Germany Purpose: To report the visual and morphological outcomes following intravitreal bevacizumab in neovascular age-related macular degeneration (nAMD) with submacular, predominantly hemorrhagic, lesions.Methods: Retrospective study of patients with a follow-up after 1 year. All eyes with submacular hemorrhages larger than 50% of the total lesion size and received only anti-VEGF (vascular endothelial growth factor) monotherapy (intravitreous administration of 1.25 mg bevacizumab, PRN). The primary endpoint was the change in hemorrhage size and time to resolution, in association with the mean best-corrected visual acuity (BCVA). The eyes were grouped based on the size of the hemorrhage: group A (≥1 to <4 disc area [DA]), group B (≥4 to <9 DA), and group C (≥9 DA).Results: Forty-six consecutive eyes were included. The mean area of the hemorrhage was 6 DA at baseline. Eyes with smaller bleeding (group A) had better chances of stabilized or improved vision. Complete resolution of the hemorrhage was seen in 96% of the eyes within 1 year. The mean BCVA increased from 0.81 logarithm of the minimum angle of resolution (logMAR) (95% confidence interval [CI]: 0.70–0.92) (Snellen 20/125) at baseline to 0.75 logMAR (95% CI: 0.62–0.88) (20/125) after 1 year (P=0.11). BCVA improved (one or more ETDRS [Early Treatment of Diabetic Retinopathy Study] lines) in 57% of the eyes (13/23) in group A; 53% (8/15) in group B; and 38% (3/8) in group C.Conclusion: Many of the eyes with hemorrhagic lesions showed stabilization or improvement of the mean BCVA after treatment within 1 year. Anti-VEGF treatment can be considered as a useful treatment option in eyes with hemorrhages secondary to nAMD. Keywords: age-related macular degeneration, bevacizumab, submacular hemorrhage
format article
author Dimopoulos S
Leitritz MA
Ziemssen F
Voykov B
Bartz-Schmidt KU
Gelisken F
author_facet Dimopoulos S
Leitritz MA
Ziemssen F
Voykov B
Bartz-Schmidt KU
Gelisken F
author_sort Dimopoulos S
title Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
title_short Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
title_full Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
title_fullStr Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
title_full_unstemmed Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
title_sort submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-vegf therapy
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/9034900ce5ab4af9b780bdcda8e03e5c
work_keys_str_mv AT dimopouloss submacularpredominantlyhemorrhagicchoroidalneovascularizationresolutionofbleedingsunderantivegftherapy
AT leitritzma submacularpredominantlyhemorrhagicchoroidalneovascularizationresolutionofbleedingsunderantivegftherapy
AT ziemssenf submacularpredominantlyhemorrhagicchoroidalneovascularizationresolutionofbleedingsunderantivegftherapy
AT voykovb submacularpredominantlyhemorrhagicchoroidalneovascularizationresolutionofbleedingsunderantivegftherapy
AT bartzschmidtku submacularpredominantlyhemorrhagicchoroidalneovascularizationresolutionofbleedingsunderantivegftherapy
AT geliskenf submacularpredominantlyhemorrhagicchoroidalneovascularizationresolutionofbleedingsunderantivegftherapy
_version_ 1718399466329866240

Ejemplares similares